NYSE:LLY - Eli Lilly and Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $200.75
Forecasted Upside: 2.73 %
Number of Analysts: 12
Breakdown:
0 Sell Ratings
2 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$195.42 As of 05/7/2021 01:00 AM ET

▲ +1.53 (0.79%)

1 month | 3 months | 12 months

Get New Eli Lilly and Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$200.75

▲ +2.73% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Eli Lilly and in the last 3 months. The average price target is $200.75, with a high forecast of $235.00 and a low forecast of $144.00. The average price target represents a 2.73% upside from the last price of $195.42.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Eli Lilly and. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/14/2019

1 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/12/2020

1 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/12/2020

1 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/10/2020

1 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

11/8/2020

1 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/6/2021

0 strong buy ratings
11 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/7/2021

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/7/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/4/2021	Barclays	Lower Price Target	Overweight	$232.00 ➝ $227.00	Medium	i
5/4/2021	Mizuho	Lower Price Target	Buy	$228.00 ➝ $216.00	N/A	i
5/4/2021	Morgan Stanley	Lower Price Target	Overweight	$217.00 ➝ $207.00	N/A	i
4/28/2021	Morgan Stanley	Lower Price Target	Overweight	$217.00 ➝ $207.00	Medium	i
4/28/2021	Mizuho	Lower Price Target	Buy	$228.00 ➝ $216.00	Medium	i
4/28/2021	Barclays	Lower Price Target	Overweight	$232.00 ➝ $227.00	Medium	i
3/22/2021	Truist Securities	Boost Price Target	Buy	$215.00 ➝ $225.00	Low	i
3/15/2021	Truist Securities	Boost Price Target	Buy	$215.00 ➝ $225.00	High	i
2/12/2021	Cowen	Boost Price Target	Outperform	$195.00 ➝ $235.00	Low	i
2/4/2021	Morgan Stanley	Boost Price Target	Overweight	$190.00 ➝ $217.00	Medium	i
2/1/2021	Truist	Boost Price Target		$200.00 ➝ $215.00	Low	i
2/1/2021	Mizuho	Boost Price Target	Buy	$222.00 ➝ $228.00	Low	i
2/1/2021	Barclays	Boost Price Target	Overweight	$190.00 ➝ $232.00	Low	i
1/22/2021	Bank of America	Boost Price Target	Buy	$195.00 ➝ $225.00	Medium	i
1/19/2021	Mizuho	Upgrade	Neutral ➝ Buy	$164.00 ➝ $222.00	N/A	i
1/12/2021	Truist	Boost Price Target		$182.00 ➝ $200.00	Medium	i
12/16/2020	Mizuho	Boost Price Target	Neutral	$156.00 ➝ $164.00	High	i
12/10/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$147.00 ➝ $183.00	Medium	i
11/17/2020	Mizuho	Lower Price Target	Neutral	$164.00 ➝ $156.00	Low	i
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$150.00	Low	i
10/28/2020	Morgan Stanley	Lower Price Target	Overweight	$176.00 ➝ $170.00	Low	i
10/23/2020	Truist	Initiated Coverage	Buy	$180.00	Medium	i
10/16/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$190.00 ➝ $200.00	Low	i
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$144.00	Medium	i
9/3/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$149.55 ➝ $176.00	High	i
8/14/2020	Morgan Stanley	Boost Price Target	Equal Weight	$148.00 ➝ $157.00	Low	i
6/29/2020	Mizuho	Boost Price Target	Neutral	$155.00 ➝ $164.00	Low	i Rating by Vamil Divan at Mizuho
6/19/2020	Bank of America	Reiterated Rating	Buy	$180.00	Low	i Rating by Geoff Meacham at Bank of America Co.
6/17/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$175.00 ➝ $190.00	Low	i
6/16/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$182.00	High	i
4/24/2020	Mizuho	Boost Price Target	Buy	$148.00 ➝ $155.00	Low	i Rating by Vamil Divan at Mizuho
4/24/2020	Cfra	Boost Price Target	Hold	$146.00 ➝ $167.00	Low	i
4/24/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$156.00 ➝ $185.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
4/20/2020	UBS Group	Downgrade	Buy ➝ Neutral	$157.00 ➝ $158.00	High	i
4/19/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low	i Rating by David Risinger at Morgan Stanley
4/15/2020	Cowen	Boost Price Target	Outperform	$145.00 ➝ $160.00	Medium	i
4/9/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$148.00	Low	i Rating by David Risinger at Morgan Stanley
4/2/2020	Mizuho	Reiterated Rating	Hold	$148.00	Medium	i Rating by Vamil Divan at Mizuho
4/2/2020	Morgan Stanley	Lower Price Target	Overweight ➝ Equal Weight	$150.00 ➝ $148.00	High	i Rating by David Risinger at Morgan Stanley
3/11/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$168.00	Medium	i
2/27/2020	Barclays	Initiated Coverage	Overweight		High	i
2/18/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
2/5/2020	Mizuho	Initiated Coverage	Neutral	$148.00	Low	i
2/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
12/30/2019	Argus	Boost Price Target	Buy	$145.00 ➝ $165.00	Low	i
12/18/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$140.00 ➝ $150.00	High	i
12/18/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$116.00 ➝ $150.00	High	i
12/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
10/17/2019	UBS Group	Lower Price Target	Buy	$134.00 ➝ $133.00	Low	i
10/16/2019	Bank of America	Initiated Coverage	Buy	$133.00	Low	i Rating by Jason Gerberry at Bank of America Co.
9/10/2019	Bank of America	Set Price Target	Neutral	$118.00 ➝ $120.00	High	i Rating by Jason Gerberry at Bank of America Co.
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$135.00	Low	i
5/1/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $133.00	Low	i
4/30/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Medium	i
4/23/2019	Edward Jones	Upgrade	Hold ➝ Buy	$117.49	Low	i
4/22/2019	BMO Capital Markets	Lower Price Target	Outperform	$130.00	Medium	i
4/14/2019	Barclays	Reiterated Rating	Buy	$140.00	Low	i
4/11/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$125.84	Low	i
3/22/2019	Credit Suisse Group	Set Price Target	Hold	$121.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
3/21/2019	Bank of America	Set Price Target	Hold	$129.00	Low	i Rating by Jason Gerberry at Bank of America Co.
3/20/2019	UBS Group	Initiated Coverage	Buy	$140.00 ➝ $74.51	Low	i
3/12/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$140.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
2/26/2019	Citigroup	Set Price Target	Hold	$124.00	Medium	i Rating by Andrew Baum at Citigroup Inc.
2/8/2019	UBS Group	Lower Price Target	Average	$107.53 ➝ $100.00	Low	i
2/4/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Low	i Rating by Louise Chen at Cantor Fitzgerald
1/23/2019	UBS Group	Initiated Coverage	Buy ➝ Buy	$131.00	Low	i
1/20/2019	Barclays	Reiterated Rating	Buy	$130.00	Low	i
12/27/2018	Argus	Reiterated Rating	Buy		Medium	i
12/24/2018	BMO Capital Markets	Boost Price Target	Outperform	$124.00 ➝ $132.00	Low	i
12/20/2018	Morgan Stanley	Set Price Target	Hold	$116.00	High	i Rating by David Risinger at Morgan Stanley
12/19/2018	BMO Capital Markets	Reiterated Rating	Buy		Low	i
12/2/2018	Citigroup	Downgrade	Buy ➝ Neutral	$113.00	Low	i Rating by Andrew Baum at Citigroup Inc.
11/26/2018	Citigroup	Downgrade	Buy ➝ Neutral	$115.00	Low	i Rating by Andrew Baum at Citigroup Inc.
11/7/2018	Societe Generale	Set Price Target	Hold	$106.00	High	i Rating by Florent Cespedes at Societe Generale
10/31/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral		Medium	i Rating by Vamil Divan at Credit Suisse Group AG
10/23/2018	Wolfe Research	Initiated Coverage	Market Perform	$119.00	Low	i
10/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$128.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
10/12/2018	Barclays	Boost Price Target	Overweight	$112.00 ➝ $120.00	Low	i Rating by Geoff Meacham at Barclays PLC
10/8/2018	Guggenheim	Initiated Coverage	Buy ➝ Buy		Low	i
10/5/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$123.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
10/4/2018	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$107.00 ➝ $130.00	High	i
10/3/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$90.00 ➝ $107.00	Medium	i
10/1/2018	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $123.00	Low	i
9/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/26/2018	JPMorgan Chase & Co.	Set Price Target	Not Rated ➝ Overweight	$117.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
9/18/2018	Barclays	Reiterated Rating	Overweight	$107.00 ➝ $112.00	Low	i Rating by Geoff Meacham at Barclays PLC
9/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$110.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/7/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$98.00 ➝ $107.00	Medium	i Rating by Geoff Meacham at Barclays PLC
7/31/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $102.00	Low	i
7/31/2018	SunTrust Banks	Reiterated Rating	Buy	$105.00	Low	i
7/25/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$90.00 ➝ $94.00	Medium	i
7/25/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$84.00 ➝ $86.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
7/25/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$80.00 ➝ $90.00	High	i Rating by Alex Arfaei at BMO Capital Markets
7/25/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $110.00	High	i Rating by Louise Chen at Cantor Fitzgerald
7/25/2018	Berenberg Bank	Downgrade	Buy ➝ Hold	$99.00	High	i
7/25/2018	The Goldman Sachs Group	Set Price Target	Neutral	$100.00	High	i
7/24/2018	Cowen	Set Price Target	Buy	$105.00	High	i Rating by Steve Scala at Cowen Inc
7/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	High	i Rating by Louise Chen at Cantor Fitzgerald
7/19/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ $89.43	$78.00 ➝ $80.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
7/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
7/17/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$86.00 ➝ $90.00	Low	i
7/15/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/13/2018	Credit Suisse Group	Set Price Target	Hold	$84.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
7/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$100.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
6/22/2018	DZ Bank	Reiterated Rating	Buy ➝ Hold		Low	i
6/21/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Underperform	$82.00 ➝ $84.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
6/11/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$100.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
6/7/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$100.00	Low	i Rating by L. Chen at Cantor Fitzgerald
5/22/2018	Barclays	Set Price Target	Buy	$98.00	Low	i Rating by Geoff Meacham at Barclays PLC
5/15/2018	Credit Suisse Group	Set Price Target	Hold	$82.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
5/10/2018	BMO Capital Markets	Reiterated Rating	Hold	$78.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
4/25/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$79.00 ➝ $78.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
4/24/2018	BMO Capital Markets	Reiterated Rating	Hold	$79.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
4/22/2018	Credit Suisse Group	Set Price Target	Hold	$80.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
4/18/2018	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by Swayampakula Ramakanth at HC Wainwright
4/13/2018	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$74.00 ➝ $79.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
4/13/2018	Jefferies Financial Group	Set Price Target	Buy	$90.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/4/2018	BMO Capital Markets	Reiterated Rating	Sell	$74.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
3/23/2018	Jefferies Financial Group	Reiterated Rating	Buy	$91.00	Medium	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$93.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/26/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$105.00	Medium	i Rating by Chris Schott at JPMorgan Chase & Co.
2/2/2018	Credit Suisse Group	Reiterated Rating	Hold	$80.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
2/1/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$88.00 ➝ $86.00	Low	i
2/1/2018	BMO Capital Markets	Boost Price Target	Underperform ➝ Underperform	$73.00 ➝ $74.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
1/22/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$82.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
1/16/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	High	i
1/16/2018	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$86.98 ➝ $95.00	High	i
1/5/2018	Argus	Upgrade	Hold ➝ Buy	$85.52 ➝ $115.00	Medium	i
12/13/2017	Credit Suisse Group	Reiterated Rating	Hold		Medium	i Rating by Vamil Divan at Credit Suisse Group AG
12/12/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
12/5/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
11/21/2017	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$86.00 ➝ $90.00	N/A	i Rating by David Risinger at Morgan Stanley
11/1/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/26/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	N/A	i
10/24/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/23/2017	SVB Leerink	Boost Price Target	Market Perform	$92.00 ➝ $93.00	N/A	i Rating by S. Fernandez at SVB Leerink LLC
10/16/2017	BMO Capital Markets	Set Price Target	Sell	$73.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/13/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$105.00	N/A	i
10/13/2017	Barclays	Boost Price Target	Overweight	$90.00 ➝ $98.00	N/A	i
10/10/2017	BMO Capital Markets	Boost Price Target	Underperform	$71.00 ➝ $73.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
10/10/2017	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$84.23 ➝ $88.00	N/A	i
10/6/2017	Morgan Stanley	Set Price Target	Hold	$86.00	N/A	i Rating by David Risinger at Morgan Stanley
10/5/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$92.00 ➝ $95.00	N/A	i
10/4/2017	Cowen	Reiterated Rating	Buy	$95.00	Low	i Rating by Steve Scala at Cowen Inc
9/28/2017	BMO Capital Markets	Reiterated Rating	Sell	$71.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
9/15/2017	Morgan Stanley	Reiterated Rating	Hold	$86.00	Low	i Rating by David Risinger at Morgan Stanley
9/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00 ➝ $89.00	Low	i
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$103.00 ➝ $105.00	Low	i Rating by Richard Purkiss at Piper Jaffray Companies
9/6/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00 ➝ $71.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
8/31/2017	Jefferies Financial Group	Reiterated Rating	Buy	$89.00	Medium	i
8/31/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$103.00	Low	i Rating by Richard Purkiss at Piper Jaffray Companies
8/31/2017	SVB Leerink	Reiterated Rating	Hold		Low	i Rating by S. Fernandez at SVB Leerink LLC
8/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00 ➝ $89.00	Low	i
8/16/2017	BMO Capital Markets	Reiterated Rating	Sell	$73.00	High	i Rating by Alex Arfaei at BMO Capital Markets
8/4/2017	Berenberg Bank	Reiterated Rating	Buy	$98.00	Low	i
8/4/2017	BMO Capital Markets	Reiterated Rating	Sell	$73.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
7/27/2017	Berenberg Bank	Reiterated Rating	Buy	$100.00	Low	i
7/26/2017	UBS Group	Downgrade	Hold	$85.00	Medium	i Rating by Marc Goodman at UBS Group AG
7/26/2017	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$90.00 ➝ $90.00	Low	i
7/26/2017	BMO Capital Markets	Reiterated Rating	Underperform	$73.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
7/26/2017	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$93.00 ➝ $90.00	Low	i Rating by S. Fernandez at SVB Leerink LLC
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$90.00 ➝ $91.00	Low	i
7/13/2017	Jefferies Financial Group	Reiterated Rating	Buy	$93.00 ➝ $96.00	Low	i
7/4/2017	Citigroup	Reiterated Rating	Buy	$100.00	Low	i Rating by Andrew Baum at Citigroup Inc.
7/4/2017	Barclays	Boost Price Target	Overweight	$85.00 ➝ $90.00	Low	i Rating by Paul Choi at Barclays PLC
6/22/2017	Jefferies Financial Group	Reiterated Rating	Buy	$93.00	Low	i
6/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$92.00	Low	i
5/30/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
5/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform	$88.00	Medium	i
5/16/2017	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy ➝ Buy	$92.00	High	i
4/29/2017	BMO Capital Markets	Reiterated Rating	Underperform	$71.00 ➝ $73.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
4/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00 ➝ $92.00	Low	i
4/27/2017	Argus	Downgrade	Buy ➝ Hold	$64.18 ➝ $81.00	Low	i
4/25/2017	BMO Capital Markets	Set Price Target	Sell	$71.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
4/19/2017	Citigroup	Boost Price Target	Buy	$92.00 ➝ $100.00	Low	i Rating by Andrew Baum at Citigroup Inc.
4/19/2017	Credit Suisse Group	Reiterated Rating	Outperform	$87.00	Low	i
4/17/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	Medium	i Rating by Richard Purkiss at Piper Jaffray Companies
4/17/2017	Cowen	Boost Price Target	Outperform	$85.00 ➝ $95.00	Medium	i
4/17/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$82.00	High	i Rating by David Risinger at Morgan Stanley
4/17/2017	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform	$73.00 ➝ $71.00	High	i Rating by Alex Arfaei at BMO Capital Markets
4/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$97.00	Low	i
4/7/2017	Barclays	Boost Price Target	Overweight	$85.00 ➝ $90.00	Low	i
4/6/2017	Citigroup	Reiterated Rating	Buy	$100.00	Low	i Rating by Andrew Baum at Citigroup Inc.
3/21/2017	Credit Suisse Group	Reiterated Rating	Buy		Low	i
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low	i
3/20/2017	UBS Group	Boost Price Target	Neutral ➝ Neutral	$70.00 ➝ $85.00	N/A	i
3/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$95.00 ➝ $97.00	N/A	i
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
2/1/2017	Barclays	Boost Price Target	Buy	$80.00 ➝ $85.00	N/A	i
2/1/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$70.00 ➝ $73.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
1/20/2017	Jefferies Financial Group	Boost Price Target	Buy	$90.00 ➝ $93.00	N/A	i
1/19/2017	Citigroup	Set Price Target	Buy	$100.00	N/A	i Rating by Andrew Baum at Citigroup Inc.
1/18/2017	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy	$92.00	N/A	i
1/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$87.00	N/A	i
12/21/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$82.00 ➝ $85.00	N/A	i
12/19/2016	Credit Suisse Group	Reiterated Rating	Focus List	$87.00	N/A	i Rating by Vamil Divan at Credit Suisse Group AG
12/16/2016	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$73.00 ➝ $82.00	N/A	i Rating by David Risinger at Morgan Stanley
12/15/2016	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		N/A	i
12/14/2016	BMO Capital Markets	Reiterated Rating	Hold	$64.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
12/7/2016	Sanford C. Bernstein	Reiterated Rating	Overweight		N/A	i
11/26/2016	SVB Leerink	Reiterated Rating	Outperform	$102.00 ➝ $92.00	N/A	i Rating by Seamus Fernandez at SVB Leerink LLC
11/26/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
11/25/2016	Atlantic Securities	Downgrade	Overweight ➝ Neutral		N/A	i
11/24/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$85.00	N/A	i Rating by Chris Schott at JPMorgan Chase & Co.
11/24/2016	Morgan Stanley	Set Price Target	Hold	$73.00	N/A	i Rating by David Risinger at Morgan Stanley
11/23/2016	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$91.00 ➝ $64.00	N/A	i
11/8/2016	Citigroup	Reiterated Rating	Buy		N/A	i
10/28/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00 ➝ $100.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/27/2016	Societe Generale	Reiterated Rating	Hold	$78.00	N/A	i
10/26/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$95.00	N/A	i
10/9/2016	SVB Leerink	Reiterated Rating	Buy	$103.00	N/A	i Rating by Seamus Fernandez at SVB Leerink LLC
10/3/2016	BMO Capital Markets	Reiterated Rating	Buy	$94.00	N/A	i
9/27/2016	BMO Capital Markets	Reiterated Rating	Outperform	$94.00	N/A	i
9/27/2016	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$89.00 ➝ $95.00	N/A	i
9/20/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A	i Rating by gregg gilbert at Deutsche Bank Aktiengesellschaft
9/14/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/8/2016	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$92.00 ➝ $95.00	N/A	i
8/13/2016	SVB Leerink	Reiterated Rating	Outperform	$105.00	N/A	i Rating by Seamus Fernandez at SVB Leerink LLC
8/3/2016	Citigroup	Reiterated Rating	Buy		N/A	i
8/2/2016	Argus	Boost Price Target	Buy	$90.00 ➝ $95.00	N/A	i
7/27/2016	BMO Capital Markets	Reiterated Rating	Buy	$94.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
7/14/2016	Jefferies Financial Group	Boost Price Target	Buy	$100.00 ➝ $105.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/6/2016	Credit Suisse Group	Reiterated Rating	Buy	$91.00	N/A	i Rating by Vamil Divan at Credit Suisse Group AG
6/28/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Vamil Divan at Credit Suisse Group AG
6/26/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Seamus Fernandez at SVB Leerink LLC
6/15/2016	SunTrust Banks	Reiterated Rating	Buy		N/A	i Rating by John Boris at SunTrust Banks, Inc.
6/4/2016	Morgan Stanley	Reiterated Rating	Hold	$88.00	N/A	i Rating by David Risinger at Morgan Stanley
5/26/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Vamil Divan at Credit Suisse Group AG
5/25/2016	UBS Group	Reiterated Rating	Hold	$82.00	N/A	i
5/13/2016	Jefferies Financial Group	Reiterated Rating	Buy	$100.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.

(Data available from 5/8/2016 forward)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $195.42

$193.90

$196.27

50 Day Range

MA: $185.56

$180.17

$193.89

52 Week Range

Now: $195.42

$129.21

$218.00

Volume

2,525,643 shs

Average Volume

4,044,938 shs

Market Capitalization

$187.41 billion

P/E Ratio

31.93

Dividend Yield

1.75%

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and?

The following sell-side analysts have issued reports on Eli Lilly and in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, Cowen Inc, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Sanford C. Bernstein, Truist, Truist Securities, and Wolfe Research.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and?

12 Wall Street analysts have set twelve-month price targets for Eli Lilly and in the last year. Their average twelve-month price target is $200.75, suggesting a possible upside of 2.7%. Cowen Inc has the highest price target set, predicting LLY will reach $235.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $144.00 for Eli Lilly and in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and?

Eli Lilly and currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LLY will outperform the market and that investors should add to their positions of Eli Lilly and.
View the latest ratings for LLY.

What other companies compete with Eli Lilly and?

Other companies that are similar to Eli Lilly and include Johnson & Johnson, Pfizer, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Supernus Pharmaceuticals and Endo International.

How do I contact Eli Lilly and's investor relations team?

Eli Lilly and's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is 317-276-2000 and its investor relations email address is [email protected] The official website for Eli Lilly and is www.lilly.com.